1. Medtech Insight
  2. >>Archive

MEETINGS - UK Spongiform Encephalopathy Advisory Committee holds the following meeting open to the public (UK) September 2001:

The UK Spongiform Encephalopathy Advisory Committee (SEAC) is to open to the public the morning session of its September meeting, held in London on September 18 2001. The meeting will provide an insight into the workings of the SEAC and topics of interest including an update on vCJD. The agenda for the meeting has yet to be confirmed. The afternoon session will be held in private. Details from: Mair Richards of the SEAC Secretariat, at the Department for the Environment, Food and Rural Affairs, 1A Page Street, London SW1P 4PQ. Email: j.m.richards@ahbse.defra.gsi.gov.uk

The UK Spongiform Encephalopathy Advisory Committee (SEAC) is to open to the public the morning session of its September meeting, held in London on September 18 2001. The meeting will provide an insight into the workings of the SEAC and topics of interest including an update on vCJD. The agenda for the meeting has yet to be confirmed. The afternoon session will be held in private. Details from: Mair Richards of the SEAC Secretariat, at the Department for the Environment, Food and Rural Affairs, 1A Page Street, London SW1P 4PQ. Email: j.m.richards@ahbse.defra.gsi.gov.uk

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Device Sterilization Plants Get Extra 2 Years To Comply On EtO Phase-Out

 
• By Elizabeth Orr

The exemption, which President Donald Trump announced on July 17, is intended to cut the risk of critical device shortages. Stakeholders say the technology needed to cut emissions to required levels is not yet widely available.

Numerous Injuries Prompt Class I Recall Of Dexcom CGM Receivers

 
• By Brian Bossetta

Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.

J&J Bets On Robotics, Cardiovascular To Grow Medtech As Tariff Hit Eases, US Manufacturing Grows

 
• By Shubham Singh

Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.